Boston Scientific has announced a robust 11.5% year-over-year net sales increase in emerging markets, complementing its raised organic growth guidance to 15.5%. As the company maintains its full-year 2025 tariff impact estimate at $100 million, its favorable Zacks Rank of #2 (Buy) reflects confidence in its continued market performance. Despite recent stock fluctuations, Boston Scientific's strong operational metrics, including an operating margin of 28.6% and a projected earnings per share between $3.02 and $3.04, underscore its strategic positioning in the medical device sector.
“Boston Scientific · number of stock splits · 2 · true”
“Boston Scientific · has a market capitalization of · $144.97 billion”
“Zacks Rank · for Boston Scientific is · #2 (Buy)”
“Boston Scientific · has an earnings yield of · 3.5% · compared to the industry's 2.5%”
“Boston Scientific · recorded a net sales increase of · 11.5% · in emerging markets year over year”
“Boston Scientific · maintains its full-year 2025 tariff impact estimate of · $100 million”
“Boston Scientific Corp. · engages in · the development, manufacture, and marketing of medical devices · true”
“Boston Scientific · operates through · the MedSurg and Cardiovascular segments · true”
“Boston Scientific · has employees · 59,000 · true”
“Boston Scientific · is headquartered in · Marlborough, Massachusetts · true”
“Boston Scientific · was founded in · 1979 · true”
“Boston Scientific · announced an investment of · $1.5 billion in return for a 34% stake in MiRus · true”
